Is PDS Biotechnology Corporation (PDSB) a Buy, Sell, or Hold?
NASDAQ : PDSB
PDS Biotechnology Corporation
$0.2568 USD
-$0.47 (-64.87%)
- Volume
- 26.75M
- Average Volume
- 795.78K
- Market Capitalization
- $14.36M
- P/E Ratio
- -0.38
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $1.55
- Year Low
- $0.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.26
Company Overview
NASDAQ
Frank K. Bedu-Addo
Biotechnology
Healthcare
PDSB
21
US
USD
Liquidity Metrics
4.07
2.26
2.26
2.13
0.00
Sales & Valuation
-$
0.00
3.66
0.00
-79.11
Profitability
-$0.74
-$34.5M
0.00%
0.00%
-346.03%
-135.25%
P/E Metrics
-0.38
-0.01
-0.01
Analyst Price Target & Rating
$9.00
$9.00
$9.00
1/5
7 Analysts
-97.15%
Financial Health Scores
-14.58
0/9
$12.74M
$24.66M
$20.77M
-$27.93M
Key Metrics (TTM)
$35.09M
0.00
-1.26
2.26
-346.03%
-146.60%
-82.21%
-10738.48%
0 days
Company Executives
| Name | Title |
|---|---|
| Gregory L. Conn | Chief Scientific Officer |
| Kirk V. Shepard | Chief Medical Officer |
| Lars Robert Boesgaard | Principal Financial & Accounting Officer and Chief Financial Officer |
| Stephan Toutain | Chief Operating Officer |
| Janetta Trochimiuk | Controller |
| Spencer Brown | Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer |
| Frank K. Bedu-Addo | President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About PDS Biotechnology Corporation (NASDAQ:PDSB) Stock
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of mela ... noma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
2026-08-11 13:49:42
PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
2026-08-11 08:25:00
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D.
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
2026-06-10 10:56:11
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
PDS Biotechnology Q1 Earnings Call Highlights
2026-05-13 14:11:12
PDS Biotechnology NASDAQ: PDSB reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs.
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
2026-05-13 10:10:43
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
2026-05-13 07:00:00
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.
Frequently Asked Questions
-
What is the current PDS Biotechnology Corporation (PDSB) stock price?
-
PDS Biotechnology Corporation(NASDAQ:PDSB) stock price is $0.2568 in the last trading session. During the trading session, PDSB stock reached the peak price of $1.55 while $0.2308 was the lowest point it dropped to. The percentage change in PDSB stock occurred in the recent session was --64.87% while the dollar amount for the price change in PDSB stock was -$0.47.
-
PDSB's industry and sector of operation?
-
The NASDAQ listed PDSB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PDSB?
-
Gregory L. Conn | Chief Scientific Officer
Kirk V. Shepard | Chief Medical Officer
Lars Robert Boesgaard | Principal Financial & Accounting Officer and Chief Financial Officer
Stephan Toutain | Chief Operating Officer
Janetta Trochimiuk | Controller -
How many employees does PDSB have?
-
Number of PDSB employees currently stands at 21. PDSB operates from 303A College Road East, Princeton, NJ 08540, US.
-
Link for PDSB official website?
-
Official Website of PDSB is: https://www.pdsbiotech.com
-
How do I contact PDSB?
-
PDSB could be contacted at phone #800 208 3343 and can also be accessed through its website. PDSB operates from 303A College Road East, Princeton, NJ 08540, US.
-
How many shares of PDSB are traded daily?
-
The average number of PDSB shares traded daily for last 3 months was 795.78K.
-
What is the market cap of PDSB currently?
-
The market value of PDSB currently stands at $14.36M with its latest stock price at $0.2568